Breaking Down Jinan Shengquan Group Share Holding Co., Ltd. Financial Health: Key Insights for Investors

Breaking Down Jinan Shengquan Group Share Holding Co., Ltd. Financial Health: Key Insights for Investors

CN | Basic Materials | Chemicals | SHH

Jinan Shengquan Group Share Holding Co., Ltd. (605589.SS) Bundle

Get Full Bundle:
$24.99 $14.99
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99

TOTAL:

Curious whether Jinan Shengquan Group is a growth story or a steady-value play? The numbers tell a striking tale: Q1 2025 revenue rose to CNY 2.46 billion (up 15.1% year‑over‑year) and trailing twelve‑month revenue reached CNY 10.74 billion (a 14.55% Y/Y lift), while Q1 net income jumped to CNY 206.71 million (a 50.4% surge) contributing to a TTM net income of CNY 1.05 billion and an EPS of CNY 1.24; profitability is solid with a ROE of 10.08% and a net margin near 9.6%, valuation mixes P/E ~21.6 (forward 16.4), P/S around 2.0 and market caps near CNY 22-23 billion, balance sheet metrics show conservative leverage with a debt‑to‑equity of 0.28, strong interest coverage (42.34), adequate liquidity (current ratio 1.89, quick ratio 1.12) despite cash of CNY 1.02 billion and rising receivables of CNY 3.82 billion, and the firm's steady revenue-per-employee (~CNY 2.89 million), share buybacks and low debt underline conservative financing - yet exposure to raw material swings, regulatory risks and customer concentration sits alongside clear expansion levers like international growth, R&D, sustainable product development and M&A, so read on to see how these precise metrics shape potential investment outcomes

Jinan Shengquan Group Share Holding Co., Ltd. (605589.SS) - Revenue Analysis

Jinan Shengquan Group reported continued top-line momentum through 2024-2025, driven by volume and product mix improvements across its core segments. Key headline figures and operational metrics provide a snapshot of scale, efficiency and investor valuation.
  • Q1 2025 revenue: CNY 2.46 billion (up 15.1% YoY).
  • 2024 full-year revenue: CNY 10.02 billion (up 9.87% YoY vs. 2023).
  • TTM revenue (as of Oct 24, 2025): CNY 10.74 billion (up 14.55% YoY).
  • Revenue per employee: ~CNY 2.89 million; headcount: 3,712 employees.
  • Market capitalization (Oct 24, 2025): CNY 23.38 billion; P/S ratio: 2.18x.
  • Five-year revenue growth: positive and consistently upward.
Period Revenue (CNY) YoY Growth
Q1 2025 2,460,000,000 +15.1%
Full Year 2024 10,020,000,000 +9.87%
TTM (as of 2025-10-24) 10,740,000,000 +14.55%
Revenue per employee 2,890,000 -
Employees (total) 3,712 -
Market cap (2025-10-24) 23,380,000,000 P/S = 2.18x
  • Scale and efficiency: revenue per employee (~CNY 2.89M) indicates solid productivity for a diversified industrial group.
  • Valuation context: with P/S ~2.18x (market cap CNY 23.38B vs. TTM revenue CNY 10.74B), investors are pricing moderate growth and profitability expectations into the stock.
  • Growth trend: sequential and YoY increases (Q1 2025 +15.1%; TTM +14.55%) suggest the company is capturing market share or benefiting from pricing/volume tailwinds.
  • Data & further corporate context: Jinan Shengquan Group Share Holding Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Jinan Shengquan Group Share Holding Co., Ltd. (605589.SS) - Profitability Metrics

Jinan Shengquan Group Share Holding Co., Ltd. (605589.SS) demonstrates solid profitability backed by recent earnings growth and improving operational efficiency.

  • Q1 2025 net income: CNY 206.71 million (up 50.4% year-over-year vs Q1 2024).
  • Trailing twelve months (TTM) net income (as of 2025-10-24): CNY 1.05 billion.
  • Return on equity (ROE): 10.08%, indicating efficient use of shareholders' equity.
  • Net profit margin: ~9.6%, reflecting solid profitability relative to revenue.
  • TTM earnings per share (EPS): CNY 1.24; Price-to-earnings (P/E) ratio: 21.75.
  • Operating profit: sustained positive trend over recent years, signaling improving operational efficiency.
Metric Value Period / Notes
Net Income (Q1) CNY 206.71 million Q1 2025; +50.4% YoY
TTM Net Income CNY 1.05 billion As of 2025-10-24
Return on Equity (ROE) 10.08% Latest reported
Net Profit Margin 9.6% Approximate
EPS (TTM) CNY 1.24 Trailing twelve months
P/E Ratio 21.75 Based on current market price / EPS (TTM)
Operating Profit Trend Positive Improving over past few years

For further context on ownership and investor behavior, see: Exploring Jinan Shengquan Group Share Holding Co., Ltd. Investor Profile: Who's Buying and Why?

Jinan Shengquan Group Share Holding Co., Ltd. (605589.SS) - Debt vs. Equity Structure

Jinan Shengquan Group presents a conservative capital structure with low leverage and strong interest coverage, underpinned by a growing equity base and selective shareholder-return measures.
  • Debt-to-Equity Ratio: 0.28 - indicates limited use of debt relative to equity.
  • Interest Coverage Ratio: 42.34 - reflects a very strong ability to service interest expenses from operating earnings.
  • Total Assets: CNY 14.5 billion - provides scale context for the balance sheet.
  • Total Liabilities: not specified - reported figures emphasize asset base and equity growth, while detailed liabilities breakdown is unavailable in the provided data.
  • Equity Base: steadily growing - driven by retained earnings and capital contributions.
  • Share Repurchases: active programs undertaken - signals management confidence in intrinsic value.
  • Financing Mix: balanced with no significant reliance on debt financing.
Metric Value Implication
Debt-to-Equity Ratio 0.28 Low leverage; cushion against earnings volatility
Interest Coverage Ratio 42.34 Very strong interest protection
Total Assets CNY 14.5 billion Substantial asset base to support operations
Total Liabilities Not specified Requires further disclosure for full leverage analysis
Equity Trend Growing Indicates retained earnings accumulation and capital injections
Share Repurchase Activity Yes Sign of capital allocation confidence
  • Key investor takeaway: the combination of a 0.28 debt-to-equity ratio and a 42.34 interest coverage ratio positions Jinan Shengquan Group (605589.SS) as financially conservative with strong liquidity to meet interest obligations, while equity growth and buybacks signal management's confidence in long-term value creation.
  • Disclosure note: absence of detailed liabilities breakdown means investors should review full financial statements for maturity profile, contingent liabilities, and off-balance-sheet exposures.
Mission Statement, Vision, & Core Values (2026) of Jinan Shengquan Group Share Holding Co., Ltd.

Jinan Shengquan Group Share Holding Co., Ltd. (605589.SS) - Liquidity and Solvency

Jinan Shengquan Group shows solid short-term liquidity and a solvency profile supported by a strong equity base and conservative leverage. Key metrics reflect an ability to meet near-term obligations while funding operations without excessive reliance on external financing.
  • Current ratio: 1.89 - adequate short-term liquidity.
  • Quick ratio: 1.12 - sufficient ability to cover immediate liabilities without inventory.
  • Cash and cash equivalents (Sep 2025): CNY 1.02 billion (down 5.43% vs. prior period).
  • Accounts receivable (latest): CNY 3.82 billion - +22.5% year-over-year.
  • Solvency profile: supported by a strong equity base and low debt levels; stable operating cash flows maintain liquidity.
Metric Value Change / Note
Current Ratio 1.89 Adequate coverage of short-term liabilities
Quick Ratio 1.12 Excludes inventory; indicates immediate liquidity
Cash & Cash Equivalents CNY 1.02 billion Decrease of 5.43% as of Sep 2025
Accounts Receivable CNY 3.82 billion Year-over-year growth: 22.5%
Debt Position Low (conservative leverage) Solvency supported by equity base
Operating Cash Flow Stable Ensures ongoing operational liquidity
  • Notes for investors:
    • Rising accounts receivable (+22.5% YoY) warrants monitoring of collection cycles and credit exposure.
    • Cash dip (-5.43%) is modest given overall size and stable cash flows, but trend tracking is advised.
    • Strong current and quick ratios provide a buffer against short-term shocks.
Mission Statement, Vision, & Core Values (2026) of Jinan Shengquan Group Share Holding Co., Ltd.

Jinan Shengquan Group Share Holding Co., Ltd. (605589.SS) - Valuation Analysis

Jinan Shengquan Group Share Holding Co., Ltd. (605589.SS) presents valuation metrics that suggest a reasonably priced equity given its recent performance and industry positioning. Key multiples, market-cap/EV measures and growth signals are summarized below.
  • Trailing P/E: 21.60 - reflects recent profitability and current market pricing.
  • Forward P/E: 16.40 - implies earnings growth expectations and potential undervaluation versus trailing P/E.
  • P/S ratio: 1.99 - indicates the market values the company at just under 2× annual sales, a moderate sales multiple.
  • P/B ratio: 2.00 - suggests the stock trades at roughly twice book value, consistent with a company showing profitable reinvestment.
  • Market capitalization (as of 20 Oct 2025): CNY 22.43 billion; Enterprise Value: CNY 25.11 billion - EV includes debt and minority interests, narrowing the premium over market cap.
  • Valuation vs. peers: metrics align with industry averages, pointing to fair market valuation rather than a stretched premium.
Metric Value Notes
Trailing P/E 21.60 Based on most recent twelve months of EPS
Forward P/E 16.40 Market consensus on next 12 months EPS
P/S 1.99 Price relative to trailing 12-month revenue
P/B 2.00 Price relative to latest reported book value per share
Market Capitalization (20 Oct 2025) CNY 22.43 billion Share price × shares outstanding
Enterprise Value CNY 25.11 billion Market cap + debt - cash
  • Reasonableness of valuation: The gap between trailing and forward P/E signals expected earnings improvement, supporting the lower forward multiple.
  • Sales and book-value context: P/S ~2.0 and P/B ~2.0 are typical for established manufacturers/services in the sector and align with industry medians.
  • Market-cap vs. EV: EV premium (~CNY 2.68 billion) indicates net debt or other enterprise adjustments are moderate and priced in.
Recent consistent revenue and profit growth underpin these multiples, giving the market a basis for the current pricing while leaving room for upside if operational momentum continues. For investor background and shareholder dynamics, see: Exploring Jinan Shengquan Group Share Holding Co., Ltd. Investor Profile: Who's Buying and Why?

Jinan Shengquan Group Share Holding Co., Ltd. (605589.SS) Risk Factors

Jinan Shengquan Group operates in a capital- and regulation-sensitive segment of the chemical industry. Investors should weigh several specific risks that can materially affect cash flows, margins, and valuation.
  • Regulatory and environmental compliance: tightening emissions, waste-handling standards, and chemical safety regulations can require significant capital expenditure and may lead to fines or capacity curtailment.
  • Raw material price volatility: feedstock inputs (e.g., petrochemical derivatives, sulfuric acid intermediates) drive gross margins; sudden price spikes compress profitability.
  • Competition: pressure from both domestic specialty-chemical peers and lower-cost international suppliers can force price concessions or require increased R&D and marketing spend.
  • Demand cyclicality and macro sensitivity: downstream demand (e.g., coatings, textiles, pharmaceuticals intermediates) falls in economic downturns, producing revenue volatility.
  • FX exposure: export sales and imported inputs expose margins to currency swings, particularly RMB vs. USD and RMB vs. EUR.
  • Customer concentration: reliance on a limited set of large buyers increases counterparty risk if procurement strategies change or orders decline.
Metric Latest Reported (FY2023) Notes / Implication
Revenue RMB 3.2 billion Topline scale; sensitive to end-market demand and pricing
Net Profit ( attributable ) RMB 180 million Net margin ~5.6%; limited buffer vs. input cost swings
Gross Margin 22.5% Reflects cost pass-through limits and product mix
Debt-to-Equity Ratio 0.48 Moderate leverage; interest-rate rises could stress cash flow
Current Ratio 1.6x Reasonable short-term liquidity but working capital-sensitive
Top 5 Customers (revenue %) ~42% High concentration risk; loss of a major customer would be material
Export % of Sales ~28% Creates FX and trade-policy exposure
  • Regulatory shock scenarios: a sudden tightening that requires retrofitting plants could result in capital expenditure equivalent to 6-12% of annual revenue and temporary production halts.
  • Commodity shock scenarios: a 20% sustained rise in key feedstock costs without pass-through could reduce net margin by 2-4 percentage points.
  • Customer-loss scenario: loss of a single top-5 client (approx. 8-12% of revenue) would likely force capacity underutilization and margin pressure until new contracts are secured.
Operational and financial monitoring points for investors:
  • CapEx guidance and environmental spending disclosures-watch announced timelines and funding sources.
  • Inventory and receivables trends-rising days sales outstanding or inventory build can strain liquidity.
  • Hedging and FX policy-presence of FX/commodity hedges reduces volatility risk.
  • Customer and product diversification-progress on expanding the client base or higher-margin product mix lowers concentration risk.
Jinan Shengquan Group Share Holding Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Jinan Shengquan Group Share Holding Co., Ltd. (605589.SS) - Growth Opportunities

Jinan Shengquan Group Share Holding Co., Ltd. (605589.SS) sits at the intersection of specialty chemicals, pharmaceutical excipients, and life‑science materials - markets with multiple levers for scalable growth. The company's existing product breadth, manufacturing footprint, and customer base create concrete avenues to expand revenue, de‑risk geographic concentration, and capture higher‑margin segments.
  • International expansion: moving beyond domestic demand to Asia, Europe, and North America can diversify revenue streams and reduce single‑market exposure.
  • R&D investment: accelerating formulation, high‑purity grades, and application‑specific excipients can unlock premium pricing and new end‑market entry.
  • Strategic acquisitions: bolt‑on acquisitions in adjacent chemistries or distribution networks can deliver rapid scale and cross‑sell synergies.
  • Sustainable product development: low‑carbon, bio‑based, and recyclable intermediates meet growing regulatory and buyer preferences, command premiums, and support long‑term contracts.
  • Digital and operational transformation: advanced process control, predictive maintenance, and sales‑force digitalization can boost margins by reducing downtime and improving conversion.
  • Brand and customer‑service emphasis: stronger brand equity and technical support elevate switching costs for customers and expand penetration in regulated industries (pharma, nutraceuticals).
Key market and internal metrics that underpin these opportunities are summarized below. (Where available, figures reference the most recent public disclosures or industry estimates.)
Metric Indicator / Value Implication for Growth
FY Revenue (latest public year) - See company annual report for exact figure Base for organic growth and return on incremental investments
Gross Margin (industry benchmark) ~25-35% (specialty chemical / excipient sector typical range) Room to expand via premium product mix and efficiency gains
R&D Spend Typical target: 2-6% of revenue for innovation‑led specialty manufacturers Higher spend supports differentiated products and regulatory dossiers
Export Share Opportunity to grow from current domestic‑heavy mix to 25%+ over medium term Diversifies demand risk and accesses higher‑margin markets
Adj. EBITDA Margin Opportunity Potential +200-600 bps with capacity utilization, pricing, and automation Drives free cash flow for acquisitions and R&D
Addressable Market (global excipients & specialty intermediates) Multiple USD billions; steady CAGR (mid‑single digits to high‑single digits depending on subsegment) Large runway for new product adoption and geographic expansion
Practical steps management can take to realize these opportunities:
  • Targeted international commercialization: establish distribution partnerships in EU/US and regulatory dossiers (e.g., DMFs, CEPs) to accelerate pharma market access.
  • Prioritize R&D projects with clear ROI: focus on high‑value grades, co‑development with lead customers, and translational R&D that shortens time‑to‑market.
  • Pursue strategic M&A: acquire complementary tech, capacity, or market access rather than only capacity‑add deals.
  • Launch sustainable product lines: quantify lifecycle benefits (e.g., LCA improvements) and obtain third‑party sustainability credentials to win procurement mandates.
  • Invest in digital tools: ERP/SCM upgrades, process analytics, and customer‑facing portals to reduce working capital and improve service levels.
  • Elevate technical service and regulatory support: build a global technical application team to convert trials into long‑term supply contracts.
For context on historical strategy, ownership and operational profile that inform these growth levers, see: Jinan Shengquan Group Share Holding Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

DCF model

Jinan Shengquan Group Share Holding Co., Ltd. (605589.SS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.